Skip to main content


Dr Carmine Gentile, PharmD/PhD, FAHA, leads the Cardiovascular Regeneration Group working on 3D bioprinting and stem cell technologies both at the Heart Research Institute (HRI) and UTS. He is a Senior Lecturer (Faculty) within the School of Biomedical Engineering (Faculty of Engineering and IT) at the University of Technology Sydney.

He received his BSc/MSc (Pharmaceutical Chemistry and Technologies) and PharmD at the University of Pisa, Italy and his PhD in Biomedical Sciences (Cardiovascular) at the Medical University of South Carolina, Charleston, SC, USA, funded by a prestigious American Heart Association Fellowship.

Since 2013 Dr Gentile has worked in Australia at HRI, The University of Sydney and now at UTS, supported by several awards and grants, working within a multidisciplinary team with scientists, industry partners and clinicians to quickly translate his findings from bench to bedside.

Dr Gentile is an internationally recognised expert in the field of 3D bioprinting and stem cell technologies, and his more recent studies focus on novel molecular and cellular approaches to treat cardiovascular disease, including myocardial infarction and heart failure. These studies are based on the use of “mini-hearts” he developed as “bioink” for human heart tissues. In 2016, he was invited as Visiting Research Fellow at Harvard Medical School, where he worked towards novel in-vitro models using mini-hearts to study human heart physiology.